Bacoside, a major active component of Bacopa monnieri (commonly known as Brahmi), has been investigated for its neuroprotective properties in several preclinical and limited clinical studies. Its use in supporting or treating stroke is primarily based on scientific exploration rather than traditional practice. Animal studies have suggested that bacosides may exert neuroprotective effects through antioxidant activity, modulation of neurotransmitters, anti-inflammatory properties, and by reducing oxidative stress and neuronal damage following ischemic injury (such as that caused by stroke). For example, research in rodent models has shown that administration of bacosides can reduce infarct size and improve neurological outcomes after induced stroke, likely by mitigating oxidative damage and supporting mitochondrial function (Phytomedicine, 2011).

However, direct clinical evidence in humans is sparse. Most of the supportive data come from animal models or in vitro studies rather than large-scale human trials. While some small studies on Bacopa monnieri suggest cognitive benefits and potential for supporting brain health, targeted research on bacoside for post-stroke recovery in humans is limited. As such, the scientific evidence is promising but preliminary, and more robust clinical trials are necessary to confirm its efficacy and safety in stroke patients.